KR100257496B1 - 골 흡수 억제용 약제학적 조성물 - Google Patents

골 흡수 억제용 약제학적 조성물 Download PDF

Info

Publication number
KR100257496B1
KR100257496B1 KR1019920024122A KR920024122A KR100257496B1 KR 100257496 B1 KR100257496 B1 KR 100257496B1 KR 1019920024122 A KR1019920024122 A KR 1019920024122A KR 920024122 A KR920024122 A KR 920024122A KR 100257496 B1 KR100257496 B1 KR 100257496B1
Authority
KR
South Korea
Prior art keywords
group
bond
bone
pharmaceutical composition
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019920024122A
Other languages
English (en)
Korean (ko)
Other versions
KR930012036A (ko
Inventor
이나즈미즈호
사토료이치
이노우에쓰토무
기타가와히로시
가토마사카즈
하인리히엥글레르트
드니까르니아또
한스-요헨랑
Original Assignee
바트 루디거
훽스트쟈판가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바트 루디거, 훽스트쟈판가부시키가이샤 filed Critical 바트 루디거
Publication of KR930012036A publication Critical patent/KR930012036A/ko
Application granted granted Critical
Publication of KR100257496B1 publication Critical patent/KR100257496B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019920024122A 1991-12-16 1992-12-14 골 흡수 억제용 약제학적 조성물 Expired - Fee Related KR100257496B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP91-331,767 1991-12-16
JP33176791 1991-12-16
JP92-239,144 1992-09-08
JP23914492A JP3502403B2 (ja) 1991-12-16 1992-09-08 骨吸収抑制剤

Publications (2)

Publication Number Publication Date
KR930012036A KR930012036A (ko) 1993-07-20
KR100257496B1 true KR100257496B1 (ko) 2000-08-01

Family

ID=26534099

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920024122A Expired - Fee Related KR100257496B1 (ko) 1991-12-16 1992-12-14 골 흡수 억제용 약제학적 조성물

Country Status (10)

Country Link
US (1) US5317029A (enExample)
EP (1) EP0547545B1 (enExample)
JP (1) JP3502403B2 (enExample)
KR (1) KR100257496B1 (enExample)
AT (1) ATE114465T1 (enExample)
CA (1) CA2085421A1 (enExample)
DE (1) DE69200757T2 (enExample)
DK (1) DK0547545T3 (enExample)
ES (1) ES2066546T3 (enExample)
TW (1) TW223016B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
US5389646A (en) * 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
KR100389127B1 (ko) * 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TWI396543B (zh) * 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZM7682A1 (en) * 1981-09-25 1983-05-23 Beecham Group Plc Active compounds
EP0091748B1 (en) * 1982-04-08 1986-06-18 Beecham Group Plc Antihypertensive benzopyranols
JPS58219183A (ja) * 1982-04-28 1983-12-20 ビ−チヤム・グル−プ・ピ−エルシ− 新規なクロマノ−ル，その製法及びそれらを含む製薬組成物
EP0093535B1 (en) * 1982-04-28 1986-12-30 Beecham Group Plc Novel chromenes and chromans
GB8513369D0 (en) * 1985-05-28 1985-07-03 Beecham Group Plc Treatment
DE3703227A1 (de) * 1987-02-04 1988-08-18 Hoechst Ag Substituierte 3,4-dihydro-2h-benzopyrane, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate

Also Published As

Publication number Publication date
EP0547545A1 (en) 1993-06-23
CA2085421A1 (en) 1993-06-17
JPH05221860A (ja) 1993-08-31
TW223016B (enExample) 1994-05-01
US5317029A (en) 1994-05-31
EP0547545B1 (en) 1994-11-30
DE69200757D1 (de) 1995-01-12
ATE114465T1 (de) 1994-12-15
DK0547545T3 (da) 1995-05-15
KR930012036A (ko) 1993-07-20
JP3502403B2 (ja) 2004-03-02
DE69200757T2 (de) 1995-05-11
ES2066546T3 (es) 1995-03-01

Similar Documents

Publication Publication Date Title
KR100257496B1 (ko) 골 흡수 억제용 약제학적 조성물
AU629443B2 (en) Composition and method for the treatment of osteoporosis in mammals
KR100638684B1 (ko) 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
RU97115713A (ru) Соединения, содержащие бензопиран и способ их применения
JPH10504574A (ja) 静脈内注入用アレンドロナート組成物
AU666514B2 (en) Method and composition for the treatment of osteoporosis
EP0135172A2 (en) Method for treatment of osteoporosis
EP0140998B1 (en) Ophthalmic preparations
US5604199A (en) Method of treating fibrosis in skeletal muscle tissue
WO2004110458A1 (en) Phenothiazine enantiomers as agents for the prevention of bone loss
AU748861B2 (en) Method of mitigating the adverse effects of interleukin-2
EP0207505A2 (en) Use of a prenyl ketone in the preparation of a medicament against gastritis
US5726148A (en) Method of treating metabolic bone diseases with an IL-1 receptor
EP0800397A1 (en) Bone mass anabolic composition comprising olpadronate
KR100718030B1 (ko) 변형성 관절증 치료제
US6333327B2 (en) Method for the treatment of Multiple Sclerosis
EP0321556A1 (en) Use of c-5 mono-substituted barbiturates to treat disorders of uric acid metabolism
US5888991A (en) Use of phosphorus derivatives of alkaloids for treating endocrinopathies
EP0087744B1 (en) Lipid metabolism improving agents
WO1991004047A1 (en) Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
EP1261344B1 (en) Use of indoloquinoxalines for the treatment of multiple sklerosis
EP1496057A1 (en) Novel crystal of quinoxalinedione derivative anhydride
EP0477871A2 (en) Antiviral composition, containing guanine derivatives
NILSSON et al. Effect of interferon on heterotopic new bone formation in mice
JPH0395116A (ja) 逆転写酵素阻害組成物

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20030303

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20030303